PQQ (pyrroloquinoline quinone) trials recruiting now

1 registration that name PQQ as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.

Trial Finder Read from ClinicalTrials.gov Oct 20, 2026 The PQQ (pyrroloquinoline quinone) supplement page

Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.

Filter 1 registration

Status

All 1 registrations

Not yet recruitingNCT07393464

PQQ for Cognitive and Negative Symptoms

  • No phase
  • Tianjin Anding Hospital
  • About 70 people
  • Starts Feb 15, 2026 (estimated)

In plain words A study of PQQ in people 18 to 50, run by Tianjin Anding Hospital. It plans to enroll about 70 people and lists no sites yet.

Who it lists and where

Who the trial lists, as registered

Lists people 18 to 50. Conditions: Schizophrenia; Cognitive Symptoms; Negative Symptoms.

What it tests, as registered

Pyrroloquinoline quinone (PQQ); placebo (dietary fiber)

Registered summary

Schizophrenia is a complex mental disorder characterized by a range of symptoms, including negative symptoms and cognitive impairments. Recent research has indicated the potential benefits of targeting mitochondrial dysfunction, oxidative stress, and inflammatory responses in alleviating symptoms of schizophrenia. However, the results remain inconsistent across various studies. This study aims to evaluate the efficacy of Pyrroloquinoline quinone (PQQ) in reducing negative symptoms and improving cognitive function in patients with chronic schizophrenia. The full summary is on the listing.

Where, as registered

No sites listed yet.

Also on Kymata

Supplement brands we have checkedEvery supplement brand we have reviewed.

Educational only. Not medical advice. Some links earn us a commission: kymatahealth.com/affiliate-disclosure.